Kewaunee Scientific Co. (NASDAQ:KEQU - Get Free Report) CEO Thomas David Hull III sold 2,000 shares of the firm's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $63.01, for a total value of $126,020.00. Following the completion of the sale, the chief executive officer now owns 42,497 shares in the company, valued at approximately $2,677,735.97. This represents a 4.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kewaunee Scientific Price Performance
Shares of KEQU traded up $0.19 during trading hours on Friday, hitting $63.81. 46,649 shares of the company were exchanged, compared to its average volume of 17,531. The company has a market capitalization of $183.13 million, a PE ratio of 10.11 and a beta of 0.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.53 and a quick ratio of 2.00. The firm has a fifty day simple moving average of $41.99 and a 200-day simple moving average of $43.12. Kewaunee Scientific Co. has a one year low of $27.00 and a one year high of $66.15.
Institutional Investors Weigh In On Kewaunee Scientific
Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its holdings in shares of Kewaunee Scientific by 18,000.0% during the third quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company's stock valued at $30,000 after buying an additional 900 shares in the last quarter. Barclays PLC purchased a new position in shares of Kewaunee Scientific during the third quarter valued at $121,000. Geode Capital Management LLC grew its holdings in shares of Kewaunee Scientific by 8.9% during the third quarter. Geode Capital Management LLC now owns 23,784 shares of the technology company's stock valued at $792,000 after buying an additional 1,941 shares in the last quarter. State Street Corp purchased a new position in shares of Kewaunee Scientific during the third quarter valued at $266,000. Finally, De Lisle Partners LLP grew its stake in Kewaunee Scientific by 36.6% in the third quarter. De Lisle Partners LLP now owns 42,958 shares of the technology company's stock valued at $1,446,000 after purchasing an additional 11,511 shares in the last quarter. 32.69% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded Kewaunee Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, December 18th.
View Our Latest Analysis on KEQU
About Kewaunee Scientific
(
Get Free Report)
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.
Featured Articles
Before you consider Kewaunee Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kewaunee Scientific wasn't on the list.
While Kewaunee Scientific currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
